Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain. - Trial NCT06321731
Access comprehensive clinical trial information for NCT06321731 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 500 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
AstraZeneca
Timeline & Enrollment
N/A
Jun 10, 2024
Nov 30, 2024
Primary Outcome
Annualized rate of exacerbations after BGF initiation
Summary
The aim of the ORESTES study is to describe the characteristics of the COPD patients
 initiating Trixeo (BGF -budesonide/glycopyrronium/formoterol) in Spain and to assess their
 real-world outcomes up to 12 months afterwards.
 
 For that purpose,a descriptive, observational, multi-centre, longitudinal, retrospective
 cohort study involving ~20 Spanish centres and aiming to include between 500 and 700
 patients, has been designed.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06321731
Non-Device Trial